Media stories about Cambrex (NYSE:CBM) have been trending positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cambrex earned a daily sentiment score of 0.27 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.5466416190962 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Discussion stirs around Cambrex Corporation (NYSE:CBM) this week; here is what analysts are saying. – Flаtlаnd Nеws (flatlandnews.com)
- Cleantech Building Materials: Application to Wiener Börse (finance.yahoo.com)
- Free Post Earnings Research Report: Cambrex Achieved Record Quarterly Revenue; EPS Climbed 4% (finance.yahoo.com)
- Should Value Investors Pick Cambrex (CBM) Stock? (finance.yahoo.com)
- $110.80 Million in Sales Expected for Cambrex Co. (CBM) This Quarter (americanbankingnews.com)
CBM has been the subject of a number of analyst reports. Zacks Investment Research upgraded Cambrex from a “strong sell” rating to a “hold” rating in a research note on Monday, January 15th. Longbow Research downgraded Cambrex from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 14th. Finally, William Blair initiated coverage on Cambrex in a research note on Tuesday, January 16th. They issued an “outperform” rating for the company. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $60.00.
Cambrex (NYSE:CBM) opened at $54.50 on Tuesday. The firm has a market capitalization of $1,837.78, a P/E ratio of 17.75, a price-to-earnings-growth ratio of 1.33 and a beta of 2.38. Cambrex has a one year low of $42.55 and a one year high of $62.95.
Cambrex (NYSE:CBM) last posted its quarterly earnings results on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.17. The firm had revenue of $182.28 million during the quarter, compared to the consensus estimate of $181.39 million. Cambrex had a return on equity of 22.42% and a net margin of 19.17%. The business’s revenue was up 2.5% compared to the same quarter last year. During the same period last year, the company earned $1.23 earnings per share. equities analysts forecast that Cambrex will post 2.81 EPS for the current fiscal year.
WARNING: “Cambrex (CBM) Receives Daily News Sentiment Score of 0.27” was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.thelincolnianonline.com/2018/03/20/cambrex-cbm-receives-daily-news-sentiment-score-of-0-27.html.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.